

# Sharon J Hutchinson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5694008/sharon-j-hutchinson-publications-by-year.pdf>

**Version:** 2024-02-21

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172  
papers

6,924  
citations

41  
h-index

79  
g-index

191  
ext. papers

8,319  
ext. citations

6.4  
avg, IF

5.68  
L-index

#	Paper	IF	Citations
172	Examining the impact of the first wave of COVID-19 and associated control measures on interventions to prevent blood-borne viruses among people who inject drugs in Scotland: an interrupted time series study.. <i>Drug and Alcohol Dependence</i> , <b>2022</b> , 232, 109263	4.9	2
171	Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making <b>2022</b> , 1, 129-136		
170	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , <b>2021</b> ,	4.0	12
169	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
168	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , <b>2021</b> , 3, 100384	10.3	1
167	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. <i>Addiction</i> , <b>2021</b> , 116, 2893-2907	4.6	9
166	Evaluation of the scale-up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak. <i>International Journal of Drug Policy</i> , <b>2021</b> , 96, 103304	5.5	1
165	Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1246-1255	3.4	
164	The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1452-1463	3.4	1
163	High willingness to use drug consumption rooms among people who inject drugs in Scotland: findings from a national bio-behavioural survey among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2021</b> , 90, 102731	5.5	1
162	Perspectives on pre-exposure prophylaxis for people who inject drugs in the context of an hiv outbreak: A qualitative study. <i>International Journal of Drug Policy</i> , <b>2021</b> , 88, 103033	5.5	2
161	A global investment framework for the elimination of hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 535-549	13.4	12
160	Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM. <i>Aids</i> , <b>2021</b> , 35, 665-673	3.5	6
159	Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. <i>Lancet Diabetes and Endocrinology,the</i> , <b>2021</b> , 9, 82-93	18.1	112
158	The uptake of foil from needle and syringe provision services and its role in smoking or snorting heroin among people who inject drugs in Scotland. <i>International Journal of Drug Policy</i> , <b>2021</b> , 98, 103369	5.5	0
157	Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	3
156	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , <b>2020</b> , 159, 1276-1289.e7	13.3	19

155	Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 996-1002	3.4	4
154	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , <b>2020</b> , 69, 2223-2231	19.2	7
153	Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2020</b> , 77, 102663	5.5	23
152	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 270-280	3.4	14
151	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , <b>2020</b> , 40, 260-270	7.9	14
150	The reported Qlear cut time association between interferon-free treatment and HCCQs anything but clear cut. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1034-1035	13.4	1
149	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003374	11.6	36
148	aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1368-1378	13.4	41
147	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235715	3.7	7
146	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 948-953	18.8	7
145	Global hepatitis C elimination: an investment framework. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 927-939	18.8	16
144	Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. <i>BMJ, The</i> , <b>2020</b> , 371, m3582	5.9	153
143	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study <b>2020</b> , 17, e1003374		
142	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study <b>2020</b> , 17, e1003374		
141	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study <b>2020</b> , 17, e1003374		
140	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study <b>2020</b> , 17, e1003374		
139	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study <b>2020</b> , 17, e1003374		
138	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data <b>2020</b> , 15, e0235715		

137	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data <b>2020</b> , 15, e0235715		
136	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data <b>2020</b> , 15, e0235715		
135	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data <b>2020</b> , 15, e0235715		
134	Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. <i>Liver International</i> , <b>2019</b> , 39, 1818-1836	7.9	25
133	Emergence of Novel Psychoactive Substance injecting associated with rapid rise in the population prevalence of hepatitis C virus. <i>International Journal of Drug Policy</i> , <b>2019</b> , 66, 30-37	5.5	8
132	Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. <i>Addiction</i> , <b>2019</b> , 114, 560-570	4.6	16
131	Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs. <i>Liver International</i> , <b>2019</b> , 39, 2244-2260	7.9	20
130	Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 425-434	6.1	3
129	Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. <i>Lancet HIV, the</i> , <b>2019</b> , 6, e315-e324	7.8	32
128	Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017. <i>JHEP Reports</i> , <b>2019</b> , 1, 81-89	10.3	42
127	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). <i>BMJ Open</i> , <b>2019</b> , 9, e029538	3	16
126	High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 519-528	3.4	25
125	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 135-184	18.8	216
124	Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 93-100	3.4	1
123	Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality - results from two surveys (2016). <i>HIV Medicine</i> , <b>2018</b> , 19 Suppl 1, 11-15	2.7	3
122	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 402-411	13.4	77
121	Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 930-938	3.4	9
120	Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era. <i>International Journal of Drug Policy</i> , <b>2018</b> , 52, 115-122	5.5	11

119	Spore forming bacteria infections and people who inject drugs: Implications for harm reduction. <i>International Journal of Drug Policy</i> , <b>2018</b> , 53, 45-54	5.5	2
118	Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. <i>Liver International</i> , <b>2018</b> , 38, 1402-1410	7.9	7
117	Reply. <i>Hepatology</i> , <b>2018</b> , 67, 1173	11.2	
116	Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. <i>Addiction</i> , <b>2018</b> , 113, 80-90	4.6	14
115	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 120-130	19.7	5
114	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. <i>Addiction</i> , <b>2018</b> , 113, 545-563	4.6	176
113	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 473-481	3.4	15
112	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 393-401	13.4	42
111	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 646-654	13.4	60
110	The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort-study. <i>Hepatology</i> , <b>2018</b> , 67, 97-107	11.2	23
109	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, 1397-1409	25.5	86
108	Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. <i>Addiction</i> , <b>2018</b> , 113, 2118-2131	4.6	13
107	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO HCV elimination targets?. <i>Addiction</i> , <b>2018</b> , 113, 1727	4.6	22
106	Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral therapies targeting patients with advanced liver fibrosis. <i>Journal of Hepatology</i> , <b>2018</b> , 68, S67	13.4	6
105	Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 174, 91-97	4.9	18
104	Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the direct-acting antiviral era. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 295-303	3.4	12
103	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. <i>Addiction</i> , <b>2017</b> , 112, 1302-1314	4.6	63
102	Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 944-954	3.4	9

101	Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort. <i>Journal of Hepatology</i> , <b>2017</b> , 66, S22-S23	13.4	11
100	Prison-based prescriptions aid Scotland's National Naloxone Programme. <i>Lancet, The</i> , <b>2017</b> , 389, 1005-1006	10.6	16
99	Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1391-1391h	7.8	17
98	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , <b>2017</b> , 9, CD012021	5.2	111
97	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 19-27	13.4	37
96	The seroprevalence of hepatitis C virus infection among children and their mothers attending for dental care in Glasgow, Scotland, United Kingdom. <i>Journal of Infection and Public Health</i> , <b>2017</b> , 10, 470-478	7.4	1
95	Assessing the impact and cost-effectiveness of needle and syringe provision and opioid substitution therapy on hepatitis C transmission among people who inject drugs in the UK: an analysis of pooled data sets and economic modelling. <i>Public Health Research</i> , <b>2017</b> , 5, 1-118	1.7	15
94	The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large real world cohort. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 398-404	2.2	1
93	A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 1009-1016	3.4	35
92	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 17-25	13.4	134
91	The Scottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162980	3.7	6
90	Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator. <i>Hepatology</i> , <b>2016</b> , 63, 1506-16	11.2	12
89	Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 596-605	3.4	7
88	PTH-104 Hospital Admissions and Associated Costs of Alcoholic Liver Disease in Scotland Between 1991 and 2011. <i>Gut</i> , <b>2016</b> , 65, A270.1-A270	19.2	
87	Engagement in a National Naloxone Programme among people who inject drugs. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 162, 236-40	4.9	26
86	Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. <i>Hepatology</i> , <b>2016</b> , 63, 1796-808	11.2	49
85	Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 165, 53-60	4.9	36
84	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. <i>Cochrane Database of Systematic Reviews</i> , <b>2016</b> , 2016,		26

83	P1271 : How should scale up of HCV antiviral treatment be prioritized? A cost-effectiveness analysis including individual and population prevention benefits. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S835	13.4	2
82	Modeling the initiation of others into injection drug use, using data from 2,500 injectors surveyed in Scotland during 2008-2009. <i>American Journal of Epidemiology</i> , <b>2015</b> , 181, 771-80	3.8	5
81	Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1041-9	5.5	22
80	Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. <i>Gut</i> , <b>2015</b> , 64, 1800-9	19.2	46
79	Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 269-77	13.4	30
78	Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis. <i>European Journal of Epidemiology</i> , <b>2015</b> , 30, 115-29	12.1	27
77	Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 154, 125-31	4.9	13
76	Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. <i>Addiction</i> , <b>2015</b> , 110, 1287-300	4.6	17
75	HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 399-408	3.4	77
74	Comparative effectiveness of antiviral treatment for hepatitis B: a systematic review and Bayesian network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 882-94	2.2	14
73	Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. <i>Current Opinion in Infectious Diseases</i> , <b>2015</b> , 28, 576-82	5.4	65
72	Cost-Effectiveness of HBV and HCV Screening Strategies--A Systematic Review of Existing Modelling Techniques. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145022	3.7	23
71	Global policy and access to new hepatitis C therapies for people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1064-71	5.5	12
70	Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. <i>Hepatology</i> , <b>2015</b> , 62, 355-64	11.2	83
69	Mortality and cause of death in a cohort of people who had ever injected drugs in Glasgow: 1982-2012. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 147, 215-21	4.9	13
68	What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 262-8	13.4	8
67	Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors. <i>PLoS ONE</i> , <b>2015</b> , 10, e0141073	3.7	22
66	Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. <i>International Journal of Drug Policy</i> , <b>2014</b> , 25, 34-52	5.5	196

65	Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 366-76	3.4	16
64	Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. <i>Journal of Clinical Virology</i> , <b>2014</b> , 61, 359-64	14.5	32
63	Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. <i>International Journal of Drug Policy</i> , <b>2014</b> , 25, 179-82	5.5	39
62	Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1118-26	13.4	18
61	Estimating the number of injecting drug users in Scotland's HCV-diagnosed population using capture-recapture methods. <i>Epidemiology and Infection</i> , <b>2014</b> , 142, 200-7	4.3	16
60	Use of laboratory-based surveillance data to estimate the number of people chronically infected with hepatitis B living in Scotland. <i>Epidemiology and Infection</i> , <b>2014</b> , 142, 2121-30	4.3	7
59	Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. <i>PLoS ONE</i> , <b>2014</b> , 9, e103345	3.7	160
58	The successful implementation of Scotland's Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective. <i>BMC Infectious Diseases</i> , <b>2014</b> , 14 Suppl 6, S7	4	9
57	Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. <i>International Journal of Epidemiology</i> , <b>2014</b> , 43, 235-48	7.8	224
56	Rise in testing and diagnosis associated with Scotland's Action Plan on Hepatitis C and introduction of dried blood spot testing. <i>Journal of Epidemiology and Community Health</i> , <b>2014</b> , 68, 1182-8	5.1	51
55	Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 25-32	3.4	48
54	Estimating prevalence of injecting drug users and associated heroin-related death rates in England by using regional data and incorporating prior information. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , <b>2014</b> , 177, 209-236	2.1	21
53	Incomplete contingency tables with censored cells with application to estimating the number of people who inject drugs in Scotland. <i>Statistics in Medicine</i> , <b>2014</b> , 33, 1564-79	2.3	25
52	Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: a comment on the results presented in JVH Special Issue. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, e167-8	3.4	2
51	P734 A SYSTEMATIC REVIEW OF INTERVENTIONS TO REDUCE ALCOHOL CONSUMPTION AMONG INDIVIDUALS WITH CHRONIC HCV INFECTION. <i>Journal of Hepatology</i> , <b>2014</b> , 60, S314-S315	13.4	5
50	Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions. <i>PLoS ONE</i> , <b>2014</b> , 9, e104515	3.7	66
49	A time since onset of injection model for hepatitis C spread amongst injecting drug users. <i>Journal of Mathematical Biology</i> , <b>2013</b> , 66, 935-78	2	12
48	The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - results from a community based survey and laboratory surveillance. <i>Travel Medicine and Infectious Disease</i> , <b>2013</b> , 11, 301-9	8.4	10



47	Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 460-6	13.4	25
46	Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing. <i>Drug and Alcohol Dependence</i> , <b>2013</b> , 133, 172-9	4.9	32
45	A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. <i>Journal of Clinical Virology</i> , <b>2013</b> , 57, 29-35	14.5	15
44	Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe. <i>International Journal of Drug Policy</i> , <b>2013</b> , 24, 85-100	5.5	19
43	A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996-2006. <i>Addiction</i> , <b>2013</b> , 108, 377-84	4.6	43
42	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. <i>BMJ Open</i> , <b>2013</b> , 3,	3	63
41	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. <i>Hepatology</i> , <b>2013</b> , 57, 451-60	11.2	42
40	Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57 Suppl 2, S39-45	11.6	228
39	Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57 Suppl 2, S80-9	11.6	248
38	Injecting drug users in Scotland, 2006: Listing, number, demography, and opiate-related death-rates. <i>Addiction Research and Theory</i> , <b>2013</b> , 21, 235-246	2.6	21
37	A record linkage study of hospital episodes for drug treatment clients in Scotland, 1996-2006. <i>Addiction Research and Theory</i> , <b>2013</b> , 21, 52-61	2.6	6
36	Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting. <i>Epidemiology and Infection</i> , <b>2013</b> , 141, 563-72	4.3	13
35	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , <b>2013</b> , 58, 1598-609	11.2	366
34	Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study. <i>International Journal of Drug Policy</i> , <b>2012</b> , 23, 24-32	5.5	50
33	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. <i>Hepatology</i> , <b>2012</b> , 55, 49-57	11.2	171
32	Detection of hepatitis C virus RNA in dried blood spots. <i>Journal of Clinical Virology</i> , <b>2012</b> , 54, 106-9	14.5	54
31	The association between alcohol use and hepatitis C status among injecting drug users in Glasgow. <i>Drug and Alcohol Dependence</i> , <b>2012</b> , 123, 180-9	4.9	6
30	Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. <i>International Journal of Drug Policy</i> , <b>2012</b> , 23, 346-52	5.5	36

29	Trends in the incidence of HIV in Scotland, 1988-2009. <i>Sexually Transmitted Infections</i> , <b>2012</b> , 88, 194-9	2.8	11
28	Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 646-55	2.2	23
27	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 1137-44	13.4	182
26	The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. <i>Addiction</i> , <b>2011</b> , 106, 1978-88	4.6	246
25	Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. <i>International Journal of Drug Policy</i> , <b>2011</b> , 22, 102-8	5.5	14
24	Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. <i>Hepatology</i> , <b>2011</b> , 54, 1547-58	11.2	48
23	Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. <i>Addiction</i> , <b>2010</b> , 105, 844-59	4.6	189
22	Meta-analysis of drug-related deaths soon after release from prison. <i>Addiction</i> , <b>2010</b> , 105, 1545-54	4.6	410
21	Targets for Hepatitis C virus test uptake and case-finding among injecting drug users: In prisons and general practice. <i>Addiction Research and Theory</i> , <b>2010</b> , 18, 421-432	2.6	3
20	Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 49-57	2.2	13
19	The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review. <i>BMC Public Health</i> , <b>2010</b> , 10, 721	4.1	22
18	Missing targets on drugs-related deaths, and a Scottish paradox. <i>International Journal of Drug Policy</i> , <b>2010</b> , 21, 155-9	5.5	7
17	Estimating current injectors in Scotland and their drug-related death rate by sex, region and age-group via Bayesian capture-recapture methods. <i>Statistical Methods in Medical Research</i> , <b>2009</b> , 18, 341-59	2.3	23
16	A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. <i>Statistical Methods in Medical Research</i> , <b>2009</b> , 18, 271-83	2.3	41
15	Association of self-reported alcohol use and hospitalization for an alcohol-related cause in Scotland: a record-linkage study of 23,183 individuals. <i>Addiction</i> , <b>2009</b> , 104, 593-602	4.6	31
14	Estimating the prevalence, incidence and cessation of injecting drug use in Glasgow 1960-2000: Combining expert opinion with capture-recapture prevalence data. <i>International Journal of Drug Policy</i> , <b>2006</b> , 17, 29-34	5.5	7
13	Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention. <i>International Journal of Drug Policy</i> , <b>2006</b> , 17, 211-221	5.5	34
12	Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 1150-9	6.9	151

11	Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. <i>Hepatology</i> , <b>2005</b> , 42, 711-23	11.2	105
10	Prior information in behavioral capture-recapture methods: demographic influences on drug injectors' propensity to be listed in data sources and their drug-related mortality. <i>American Journal of Epidemiology</i> , <b>2005</b> , 162, 694-703	3.8	27
9	Sudden rise in uptake of hepatitis B vaccination among injecting drug users associated with a universal vaccine programme in prisons. <i>Vaccine</i> , <b>2004</b> , 23, 210-4	4.1	20
8	Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. <i>Addiction</i> , <b>2003</b> , 98, 185-90	4.6	175
7	Drug-related deaths by region, sex, and age group per 100 injecting drug users in Scotland, 2000-01. <i>Lancet, The</i> , <b>2003</b> , 362, 941-4	4.0	35
6	Factors associated with injecting risk behaviour among serial community-wide samples of injecting drug users in Glasgow 1990-94: implications for control and prevention of blood-borne viruses. <i>Addiction</i> , <b>2000</b> , 95, 931-40	4.6	39
5	One-year follow-up of opiate injectors treated with oral methadone in a GP-centred programme. <i>Addiction</i> , <b>2000</b> , 95, 1055-68	4.6	43
4	Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): a population-based case-control study		3
3	Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study		10
2	Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland		7
1	Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study		1